Investigational Drug Information for AFQ056
✉ Email this page to a colleague
What is the development status for investigational drug AFQ056?
AFQ056 is an investigational drug.
There have been 25 clinical trials for AFQ056.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Syndrome. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Yale University.
Summary for AFQ056
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 88 |
| WIPO Patent Applications | 44 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2011-11-01) |
| Vendors | 34 |
Recent Clinical Trials for AFQ056
| Title | Sponsor | Phase |
|---|---|---|
| Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant | Yale University | Early Phase 1 |
| Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056 | National Institute on Drug Abuse (NIDA) | Phase 1 |
| Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056 | Novartis Pharmaceuticals | Phase 1 |
Clinical Trial Summary for AFQ056
Top disease conditions for AFQ056
Top clinical trial sponsors for AFQ056
US Patents for AFQ056
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
